Reverse resistance to immune checkpoint inhibitor in a patient with recurrent cardia cancer by intratumoral injection of recombinant human adenovirus type 5: a case report and literature review

in Cancer Immunity and Immunotherapy

• Qiu Zhao
• Min Xiao
• Jian Ma
• Cong Fu
• Qianqian Gao

Interactions between tumor-associated macrophages and regulated cell death: therapeutic implications in immuno-oncology

in Cancer Immunity and Immunotherapy

• Yifei Ge
• Lixue Jiang
• Chengru Yang
• Qingfu Dong
• Chengwu Tang
• Yi Xu
• Xiangyu Zhong

Common molecular basis for MASH and hepatitis C revealed via systems biology approach

in Cancer Immunity and Immunotherapy

• Yongwei Cheng
• Zihao Song
• Ye Liu
• Xichao Xu
• Dali Zhang
• Yigui Zou
• Liang Liu
• Yinzhen Zeng
• Wenwen Li
• Daming Bai

Landscape of targeted therapies for lung squamous cell carcinoma

in Cancer Immunity and Immunotherapy

• Qiuxuan Chen
• Xiaoshuo Zheng
• Jian Li

Th17/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target

in Cancer Immunity and Immunotherapy

• Meng-Han Huo
• Yilinuer Adeerjiang
• Ayiguzhali Abulitipu
• Umair Khan
• Xin-Xi Li
• Lei Zhang
• Ye Tian
• Sheng Jiang
• Can-Can Xu
• Xian-Zhen Chao

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

in Cancer Immunity and Immunotherapy

• Toshio Shimizu
• John Powderly
• Albiruni Abdul Razak
• Patricia LoRusso
• Kathy D. Miller
• Steven Kao
• Sarah Kongpachith
• Catherine Tribouley
• Michelle Graham
• Brian Stoll

Case report: Immune checkpoint inhibitor-induced paraneoplastic neurological syndrome in two patients: a case series

in Cancer Immunity and Immunotherapy

• Guang-Qing Shi
• Heng-Ning Lian
• Huan Wang
• Jie-Qiang Xia
• Li-Jie Ma
• Jing Zhou

Prognostic significance of systemic pan-immune-inflammation value in locally advanced cervical cancer

in Cancer Immunity and Immunotherapy

• Shu Yan
• Xin Gong
• Rui Liu
• Xiaojing Jia

Tislelizumab plus chemotherapy in metastatic extramammary Paget disease after surgery: a case report

in Cancer Immunity and Immunotherapy

• Dongxing Wang
• Chuang Huang
• Dongming Wang

Personalized three-year survival prediction and prognosis forecast by interpretable machine learning for pancreatic cancer patients: a population-based study and an external validation

in Cancer Immunity and Immunotherapy

• Buwei Teng
• Xiaofeng Zhang
• Mingshu Ge
• Miao Miao

Proteomic and transcriptomic analyses identify apo-transcobalamin-II as a biomarker of overall survival in osteosarcoma

in Cancer Immunity and Immunotherapy

• Ryan A. Lacinski
• Sebastian A. Dziadowicz
• Clark A. Roth
• Li Ma
• Vincent K. Melemai
• Brody Fitzpatrick
• Edwin Chaharbakhshi
• Tanya Heim
• Ines Lohse
• Karen E. Schoedel

Heterogeneity between subgroups of first-line chemoimmunotherapy for extensive-stage small cell lung cancer patients: a meta-analysis and systematic review

in Cancer Immunity and Immunotherapy

• Wenwen Kang
• Jing Cheng
• Luyun Pan
• Ping Zhan
• Hongbing Liu
• Tangfeng Lv
• Hedong Han
• Yong Song

Retraction: Mir-124 attenuates STAT3-mediated TH17 differentiation in colitis-driven colon cancer

in Cancer Immunity and Immunotherapy

Retrospective analysis of survival and safety of bevacizumab biosimilar and original drug combination chemotherapy in non-small cell lung cancer

in Cancer Immunity and Immunotherapy

• Xinyi Zhang
• Xiaofei Chu
• Jun Wang
• Wenjing Gu
• Xiaoyan Fu
• Jing Zhang
• Congying Wang
• Qinghui Han
• Jing Zhou
• Yongjing Zhang

Modeling epithelial-mesenchymal transition in patient-derived breast cancer organoids

in Cancer Immunity and Immunotherapy

• Neta Bar-Hai
• Rakefet Ben-Yishay
• Sheli Arbili-Yarhi
• Naama Herman
• Vered Avidan-Noy
• Tehillah Menes
• Aiham Mansour
• Fahim Awwad
• Nora Balint-Lahat
• Gil Goldinger